Genentech/MedImmune Patent Case Could Spur Tighter Licensing Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Supreme Court ruling that MedImmune can challenge the validity of a patent it had licensed could also encourage generic firms to seek declaratory judgments.
You may also be interested in...
The Cabilly Saga: New Patent, New Product, New Lawsuits
Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.
The Cabilly Saga: New Patent, New Product, New Lawsuits
Genentech seeks Benlysta royalties from HGS and GSK through enforcement of the Cabilly III patent.
Genentech May Appeal Rejection Of Cabilly Patent
U.S. Patent and Trademark Office rejects Genentech’s ’415 patent following Supreme Court ruling permitting MedImmune to challenge its validity.